385 related articles for article (PubMed ID: 19935741)
1. Cardiovascular effects of relaxin: from basic science to clinical therapy.
Du XJ; Bathgate RA; Samuel CS; Dart AM; Summers RJ
Nat Rev Cardiol; 2010 Jan; 7(1):48-58. PubMed ID: 19935741
[TBL] [Abstract][Full Text] [Related]
2. Relaxin: a new approach for the treatment of acute congestive heart failure.
Grossman J; Frishman WH
Cardiol Rev; 2010; 18(6):305-12. PubMed ID: 20926940
[TBL] [Abstract][Full Text] [Related]
3. The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.
Sasser JM
Am J Physiol Regul Integr Comp Physiol; 2013 Sep; 305(6):R559-65. PubMed ID: 23883673
[TBL] [Abstract][Full Text] [Related]
4. Peptide hormone relaxin: from bench to bedside.
Jelinic M; Marshall SA; Stewart D; Unemori E; Parry LJ; Leo CH
Am J Physiol Regul Integr Comp Physiol; 2018 Jun; 314(6):R753-R760. PubMed ID: 29412692
[TBL] [Abstract][Full Text] [Related]
5. Relaxin: review of biology and potential role in treating heart failure.
Teichman SL; Unemori E; Teerlink JR; Cotter G; Metra M
Curr Heart Fail Rep; 2010 Jun; 7(2):75-82. PubMed ID: 20424993
[TBL] [Abstract][Full Text] [Related]
6. G-Protein-coupled receptors as potential drug candidates in preeclampsia: targeting the relaxin/insulin-like family peptide receptor 1 for treatment and prevention.
Conrad KP
Hum Reprod Update; 2016 Sep; 22(5):647-64. PubMed ID: 27385360
[TBL] [Abstract][Full Text] [Related]
7. Relaxin as an anti-fibrotic treatment: Perspectives, challenges and future directions.
Samuel CS; Bennett RG
Biochem Pharmacol; 2022 Mar; 197():114884. PubMed ID: 34968489
[TBL] [Abstract][Full Text] [Related]
8. Relaxin, a pleiotropic vasodilator for the treatment of heart failure.
Teichman SL; Unemori E; Dschietzig T; Conrad K; Voors AA; Teerlink JR; Felker GM; Metra M; Cotter G
Heart Fail Rev; 2009 Dec; 14(4):321-9. PubMed ID: 19101795
[TBL] [Abstract][Full Text] [Related]
9. Relaxin family peptide receptors--from orphans to therapeutic targets.
van der Westhuizen ET; Halls ML; Samuel CS; Bathgate RA; Unemori EN; Sutton SW; Summers RJ
Drug Discov Today; 2008 Aug; 13(15-16):640-51. PubMed ID: 18675759
[TBL] [Abstract][Full Text] [Related]
10. The anti-fibrotic actions of relaxin are mediated through AT
Wang C; Pinar AA; Widdop RE; Hossain MA; Bathgate RAD; Denton KM; Kemp-Harper BK; Samuel CS
FASEB J; 2020 Jun; 34(6):8217-8233. PubMed ID: 32297670
[TBL] [Abstract][Full Text] [Related]
11. Relaxin: a novel agent for the treatment of acute heart failure.
Wilson SS; Ayaz SI; Levy PD
Pharmacotherapy; 2015 Mar; 35(3):315-27. PubMed ID: 25759289
[TBL] [Abstract][Full Text] [Related]
12. Relaxin and the Cardiovascular System: from Basic Science to Clinical Practice.
Martins RC; Pintalhão M; Leite-Moreira A; Castro-Chaves P
Curr Mol Med; 2020; 20(3):167-184. PubMed ID: 31642776
[TBL] [Abstract][Full Text] [Related]
13. 'Relaxin' the stiffened heart and arteries: the therapeutic potential for relaxin in the treatment of cardiovascular disease.
Samuel CS; Du XJ; Bathgate RA; Summers RJ
Pharmacol Ther; 2006 Nov; 112(2):529-52. PubMed ID: 16814863
[TBL] [Abstract][Full Text] [Related]
14. Relaxin for the Treatment of Acute Decompensated Heart Failure: Pharmacology, Mechanisms of Action, and Clinical Evidence.
Ng TM; Goland S; Elkayam U
Cardiol Rev; 2016; 24(4):194-204. PubMed ID: 26331289
[TBL] [Abstract][Full Text] [Related]
15. Serelaxin alleviates cardiac fibrosis through inhibiting endothelial-to-mesenchymal transition via RXFP1.
Wilhelmi T; Xu X; Tan X; Hulshoff MS; Maamari S; Sossalla S; Zeisberg M; Zeisberg EM
Theranostics; 2020; 10(9):3905-3924. PubMed ID: 32226528
[No Abstract] [Full Text] [Related]
16. Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis.
Chow BS; Kocan M; Bosnyak S; Sarwar M; Wigg B; Jones ES; Widdop RE; Summers RJ; Bathgate RA; Hewitson TD; Samuel CS
Kidney Int; 2014 Jul; 86(1):75-85. PubMed ID: 24429402
[TBL] [Abstract][Full Text] [Related]
17. Drugs of the future: the hormone relaxin.
Samuel CS; Hewitson TD; Unemori EN; Tang ML
Cell Mol Life Sci; 2007 Jun; 64(12):1539-57. PubMed ID: 17458501
[TBL] [Abstract][Full Text] [Related]
18. The vascular actions of relaxin.
Jeyabalan A; Shroff SG; Novak J; Conrad KP
Adv Exp Med Biol; 2007; 612():65-87. PubMed ID: 18161482
[TBL] [Abstract][Full Text] [Related]
19. Emerging role of serelaxin in the therapeutic armamentarium for heart failure.
Varr BC; Maurer MS
Curr Atheroscler Rep; 2014 Oct; 16(10):447. PubMed ID: 25108571
[TBL] [Abstract][Full Text] [Related]
20. Relaxin/serelaxin for cardiac dysfunction and heart failure in hypertension.
Chunduri P; Patel SA; Levick SP
Adv Pharmacol; 2022; 94():183-211. PubMed ID: 35659372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
